Comparative subcellular proteomics applied to dorsolateral prefrontal cortex from 75 individuals spanning the Alzheimer’s disease-resilience spectrum is developed, modelling protein localisation across disease.
Abstract
Proteome-wide analyses of human tissue have transformed our understanding of disease, but provide limited insight into protein localisation, a functionally informative dimension of the proteome. In Alzheimer’s disease, amyloid-β and tau exhibit aberrant localisation, yet whether spatial reorganisation extends proteome-wide has remained inaccessible to abundance-based proteomics. Here, we develop comparative subcellular proteomics applied to dorsolateral prefrontal cortex from 75 individuals spanning the Alzheimer’s disease-resilience spectrum, modelling protein localisation across disease. We identify 217 disease-associated localisation shifts enriched for endolysosomal function, intracellular trafficking, and RNA processing, and resolve tau proteoforms within insoluble aggregates. Our strongest localisation candidates show only modest differences in whole-tissue abundance, highlighting disease biology inaccessible to conventional proteomics. We validate co-localisation of CSNK1A1 with pathological tau and identify an unexpected neuronal localisation pattern for SCAI, a cancer-associated protein not previously characterised in human brain, highlighting the discovery potential of subcellular proteomics in tissue.
The clinical translational trajectory is delineated, illustrating how aberrant signatures are verified in cerebrospinal fluid and validated in plasma to support precision medicine and arguing for the necessity of "fused" multi-omics integration and Artificial Intelligence to decode the non-linear molecular logic of bra...
Arup Acharjee, Nitika Rai, Akash A. Patel et al.· Biochimica et Biophysica Act...· 0 citations
As the most prevalent neurodegenerative disorder worldwide, Alzheimer’s disease (AD) remains incompletely understood at the proteome level. In particular, current studies on amino acid (AA) substitutions have predominantly relied on genomic and transcriptomic profiling. Proteome-scale AA substitutions remain largely un...
Pei-Ze Zhao, Sheng-Zhi Lai, Shuai-Jian Dai et al.· bioRxiv· 0 citations
A hypothetical model of dynamic brain gene expression changes that track with progressive Alzheimer’s disease proteostasis is proposed and found that a beneficial brain biochemical state of higher total tau and lower phospho-Tau is associated with increased levels of synaptic, DNA damage/repair, nucleic acid metabolism...
Stephanie R. Oatman, Zachary S. Quicksall, Xue Wang et al.· Brain Communications· 0 citations
Plasma biomarkers of amyloid-associated tau phosphorylation (T1) and established tau proteinopathy (T2) can approximate Alzheimer's disease stage, but whether plasma-defined stages correspond to broader biological states is unknown. In 1,035 participants from a multicentre Korean cohort, we used a 220-plex immunoassay...
Y. Gu, J. Kim, B. Kim et al.· medRxiv· 0 citations
ABSTRACT Tau aggregation is a central pathological feature of Alzheimer's disease, yet how different forms of tau—ranging from monomers to small soluble aggregates and mature fibrils—interact with the cellular environment remains poorly understood. Here, we combine immunoaffinity proteomics with single‐molecule techniq...
Dorothea Boeken, Paula Beltran Lobo, Yun-Zhao Wu et al.· Advancement of science· 0 citations
It is demonstrated that conformationally distinct tau polymorphs associate with disease-specific interaction networks across Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies, providing molecular insight into tauopathy heterogeneity.